Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

December 15, 2025 by Alan Khadavi

Rhapsido vs Xolair vs Dupixent for Chronic Hives

Rhapsido vs Xolair vs Dupixent — which targeted treatment is right for chronic hives?

Chronic spontaneous urticaria (CSU, “chronic hives”) can be maddening: daily itch, unpredictable wheals, and flares that don’t respond to antihistamines. Over the last few years clinicians have gained new targeted options beyond antihistamines — an injectable anti-IgE (Xolair), an injectable IL-4/13 blocker (Dupixent), and most recently an oral BTK inhibitor (Rhapsido/remibrutinib). Below I compare how they work, the evidence, practical differences (route, dosing, onset), safety and access to help you understand the landscape before discussing choices with your clinician.


Quick snapshot

  • Rhapsido (remibrutinib) — oral BTK inhibitor; FDA approved Oct 2025 for adults with CSU not controlled on H1 antihistamines; pill, twice daily; rapid onset reported in trials.

  • Xolair (omalizumab) — anti-IgE monoclonal antibody; established second-line for CSU (subcutaneous injection every 4 weeks; 150 mg or 300 mg). Long real-world experience.

  • Dupixent (dupilumab) — IL-4/IL-13 pathway blocker; approved for CSU in 2025 for patients remaining symptomatic despite antihistamines; subcutaneous injection (loading dose then q2w).


How they work (mechanisms)

  • Rhapsido (remibrutinib) blocks Bruton’s tyrosine kinase (BTK) inside mast cells and other immune cells — this reduces release of histamine and pro-inflammatory mediators, and is a small-molecule (oral) approach rather than an antibody.Rhapsido (remibrutinib) wins FDA approval for chronic hives

  • Xolair (omalizumab) is an anti-IgE antibody that neutralizes free IgE and downregulates high-affinity IgE receptors on mast cells and basophils, reducing their activation. Xolair Treatment Duration for Hives

  • Dupixent (dupilumab) blocks IL-4 and IL-13 signaling (key type-2 cytokines), modulating downstream inflammatory pathways implicated in some patients with CSU. Dupixent for Hives


Evidence & effectiveness

  • Xolair has the longest track record in CSU with multiple randomized trials and real-world experience showing meaningful reductions in itch and hive counts; it’s the established biologic many guidelines reference. FDA Access Data

  • Dupixent was granted approval for CSU after recent trials showed benefit for patients still symptomatic on antihistamines; it’s now an approved alternative for eligible patients.

  • Rhapsido’s Phase 3 data showed rapid symptom improvement (some patients improving within ~2 weeks) and a subset becoming symptom-free; its approval introduces the first oral targeted BTK option for CSU.

A recent comparative/meta-analytic work (and expert reviews) suggests differences in magnitude and speed of response across agents — some analyses indicate omalizumab often shows the largest overall effect size at common trial endpoints, but network meta-analyses continue to evolve as new data (e.g., remibrutinib trials, dupilumab trials) accumulate. Individual response varies — some patients who fail one biologic respond to another.


Route, dosing & practical matters

  • Rhapsido: oral pill (convenient for people who dislike injections). Label and press materials describe twice-daily dosing with no routine lab monitoring required in trials. Novartis

  • Xolair: subcutaneous injection every 4 weeks (150 mg or 300 mg depending on response); can be administered in clinic or at home depending on insurance/programs.

  • Dupixent: subcutaneous injection with an initial loading dose (600 mg) then 300 mg every 2 weeks for adults with CSU (per label); self-injectable after training is common. Regeneron

Onset: Rhapsido trials reported symptom reductions as quickly as ~2 weeks in many patients; Xolair often shows improvement within 2–4 weeks for responders; Dupixent responses vary but meaningful benefit in trials occurred over weeks. Individual timing varies.


Safety & monitoring

  • Rhapsido (oral BTK inhibitor): trial safety profiles noted tolerability with no routine lab monitoring required per the label/press materials; as with any newer agent, longer-term safety in broader populations will continue to be characterized. Novartis

  • Xolair: long safety record — main concerns include injection-site reactions and rare reports of anaphylaxis (hence initial injections are often supervised). No routine lab monitoring is required. FDA Access Data

  • Dupixent: generally well tolerated; common adverse events include injection-site reactions and conjunctivitis in some patients; serious adverse events are uncommon but monitoring and clinical judgement are important. Regeneron

Always discuss individual risks (comorbidities, pregnancy, infection risk, drug interactions) with your prescribing clinician.


Cost & access

  • Rhapsido was launched with a reported wholesale acquisition cost of roughly $4,500 per 30-day supply (US), though actual patient out-of-pocket depends on insurance, copay assistance, and manufacturer programs.

  • Xolair and Dupixent are also high-cost specialty medications but have extensive insurance pathways and patient support programs; coverage decisions vary by insurer and prior-authorization criteria. Manufacturer co-pay assistance or specialty pharmacy support can change the patient cost substantially.


Which drug for which patient? (Practical guidance)

  • Prefer Xolair when you want the best-studied biologic with long experience in CSU, especially when prior guidelines or payer policies favor anti-IgE therapy. FDA Access Data

  • Consider Dupixent for patients who remain symptomatic on antihistamines and either can’t use or didn’t respond to Xolair — now an approved alternative option.

  • Consider Rhapsido for patients who prefer an oral treatment (pill) over injections, or for those who have not responded to or cannot access biologics — it’s a new, different mechanism (BTK inhibition) and showed relatively rapid onset in trials. Insurance coverage patterns may lag for a new drug, so prior authorization and cost discussions are key.

Because individual response is unpredictable, switching between mechanisms (anti-IgE → IL-4/13 blocker → BTK inhibitor, or vice versa) is sometimes effective — work closely with an allergist/dermatologist to sequence therapy and monitor response.


Bottom line

All three agents — Rhapsido (remibrutinib), Xolair (omalizumab) and Dupixent (dupilumab) — expand options for patients with chronic spontaneous urticaria who don’t get relief from antihistamines. They differ in mechanism (BTK vs IgE vs IL-4/13), route (oral vs injectable), dosing frequency, evidence base and cost/access. Xolair is the longest-used option with a deep evidence base; Dupixent is an approved biologic alternative; Rhapsido brings a convenient oral option and rapid effects in trials. The best choice depends on prior treatment history, comorbidities, route preference, insurance coverage, and how quickly you need symptom control.

Filed Under: Blog, Urticaria

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page